No article text was recorded for this version.
therapeutic cell persistence
Version 1 of 123 papers28 conceptsfrozen 2026-10-04
Papers in this version
- Blog: XCL1-secreting CEA CAR-T cells enhance endogenous CD8<sup>+</sup> T cell responses to tumor neoantigens to confer a long-term antitumor immunity
- Blog: Antitumor effects of intracranial injection of B7-H3-targeted Car-T and Car-Nk cells in a patient-derived glioblastoma xenograft model
- Blog: Phenoscaping Reveals Multimodal γδ T-cell Cytotoxicity as a Strategy to Overcome Cancer Cell–Mediated Immunomodulation
- Blog: 1078 The development of IL15v-NKCE: a cutting-edge NK cell engager platform for cancer treatment
- Blog: 323 TALEN<sup>®</sup>-based gene edited iPSC-derived NK (iNK) cells demonstrate enhanced antitumor activity
- Blog: Cytokines induced memory-like NK cells engineered to express CD19 CAR exhibit enhanced responses against B cell malignancies
- Blog: CAR-NK cells for cancer immunotherapy: recent advances and future directions
- Blog: 177 Preclinical characterization of CYT-100 iPSC derived NK cells alone and in combination with CYT-303 NK cell engager for hepatocellular carcinoma (HCC)
- Blog: Natural killer cell-specific chimeric antigen receptor enhances CAR NK cell functions and anti-tumor activity
- Blog: Human cancer-targeted immunity via transgenic hematopoietic stem cell progeny
- Blog: An immortal porcine preadipocyte cell strain for efficient production of cell-cultured fat
- Blog: 1320 Non-clinical characterization of CYT-303 FLEX-NK™ engager antibody supports clinical evaluation
- Blog: HER2-specific chimeric antigen receptor-T cells for targeted therapy of metastatic colorectal cancer
- Blog: CD19 chimeric antigen receptor T-cell therapy following autologous stem cell transplantation against relapsed or refractory Burkitt lymphoma/leukemia: A case report and literature review
- Blog: Improving CAR-T cell function through a targeted cytokine delivery system utilizing car target-modified extracellular vesicles
- Blog: Safety and immune cell kinetics after donor natural killer cell infusion following haploidentical stem cell transplantation in children with recurrent neuroblastoma
- Blog: Efficacy and safety of one-time autologous tumor-infiltrating lymphocyte cell therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
- Blog: Intrathecal CRISPR-edited allogeneic IL-13Rα2 CAR T Cells for recurrent high-grade Glioma: preclinical characterization and phase I trial
- Blog: Spatially optimized 125I brachytherapy: a novel immunomodulatory approach based on spatially fractionated radiation therapy principles
- Blog: A Quantitative Comparison of Anti-HIV Gene Therapy Delivered to Hematopoietic Stem Cells versus CD4+ T Cells
- Blog: Engineered CARD11–PIK3R3 T‐cell therapies as weapons of cancer mass destruction
- Blog: Bcl-xL Promotes the Survival of Motor Neurons Derived from Neural Stem Cells
- Blog: Derivation and Preclinical Characterization of CYT-303, a Novel NKp46-NK Cell Engager Targeting GPC3
History & citation
Current · Permanent link
Cite this direction
Latest version (a living page):
@misc{lacuna_therapeutic_cell_persistence_a985acf9,
title = {therapeutic cell persistence},
author = {{Lacuna}},
howpublished = {Lacuna research direction},
year = {2026},
url = {https://lacuna.tiptreesystems.com/direction/therapeutic-cell-persistence/rdr_a985acf955eb434bb566b8317e7e84b7},
note = {Latest version of a living research direction; cite a version for a fixed text. Accessed 2026-11-19},
}This exact version (version 1, frozen text):
@misc{lacuna_therapeutic_cell_persistence_a985acf9_v1,
title = {therapeutic cell persistence},
author = {{Lacuna}},
howpublished = {Lacuna research direction},
year = {2026},
url = {https://lacuna.tiptreesystems.com/direction/therapeutic-cell-persistence/rdr_a985acf955eb434bb566b8317e7e84b7/v/1},
note = {Version 1, frozen 2026-10-04. Accessed 2026-11-19},
}